A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).

J. Randolph Hecht,Aleix Prat,Miklos Pless,Antonio Cubillo,Aitana Calvo,Steven S. Raman,Jason Chesney,Chunxu Liu,Emily Chan

A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).

2018

J. Randolph Hecht
Aleix Prat
Miklos Pless
Antonio Cubillo
Aitana Calvo
Steven S. Raman
Jason Chesney
Chunxu Liu
Emily Chan

TPS3105Background: Combining the intralesional oncolytic immunotherapy T-VEC with systemic immunotherapy may enhance the systemic efficacy of both agents through complementary mechanisms of action....

Keywords:

Talimogene laherparepvec
Cancer research
Pembrolizumab
Pathology
Medicine
Immunotherapy
open label
Oncology
Oncolytic virus
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations